Quarterly ResultAug 12, 2026, 04:18 PM
Acumen Pharma Q2 Net Loss $32.7M; Going Concern Doubt Raised
AI Summary
Acumen Pharmaceuticals reported a net loss of $32.7 million for the second quarter of 2026, bringing the six-month net loss to $53.5 million. The company's cash, cash equivalents, and marketable securities stood at $110.2 million as of June 30, 2026, with an accumulated deficit of $499.9 million. Management raised substantial doubt about the company's ability to continue as a going concern, citing expected additional losses and the need for further capital. Despite financial challenges, Acumen continues to advance its sabirnetug Phase 2 ALTITUDE-AD clinical trial, with top-line results anticipated in late 2026, and nominated two EBD development candidates in June 2026.
Key Highlights
- Net loss for Q2 2026 was $32.7 million, compared to $41.0 million in Q2 2025.
- Net loss for the six months ended June 30, 2026 was $53.5 million.
- Cash, cash equivalents, and marketable securities totaled $110.2 million as of June 30, 2026.
- Accumulated deficit reached $499.9 million as of June 30, 2026.
- Research and development expenses were $27.8 million for Q2 2026.
- Company raised substantial doubt about its ability to continue as a going concern.
- Proceeds from a private placement in Q1 2026 amounted to $35.4 million.
- Top-line results for the Phase 2 ALTITUDE-AD clinical trial are expected in late 2026.
Price Impact
More from ABOS